A case of panitumumab-responsive metastatic rectal cancer initially refractory to cetuximab

Yuta Kasagi, Eiji Oki, Koji Ando, Yasue Kimura, Toru Ikegami, Hiroshi Saeki, Masaru Morita, Tetsuya Kusumoto, Yoshihiko Maehara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A 64-year-old man was initially diagnosed with rectal cancer and liver metastasis. He underwent rectal amputation and partial hepatectomy. mFOLFOX6 was begun as first-line chemotherapy, but multiple pulmonary and right femoral lymph node metastases were found 1 year postoperatively. FOLFIRI plus bevacizumab was then started, but the tumors recurred after 2 years and 11 months. The regimen was changed to cetuximab with CPT-11. The lesions partially responded after 3 months, and the patient was free from progression for 1.5 years. Four years and 7 months after the adjuvant chemotherapy was started, the metastatic lesions gradually increased again, and the regimen was changed to panitumumab. After 2 months, the lesions had markedly decreased again and showed a partial response for 6 months. Although the pulmonary lesions became progressive again, the patient has been alive for 5 years and 8 months since the first operation.

Original languageEnglish
Pages (from-to)382-386
Number of pages5
JournalCase Reports in Oncology
Volume6
Issue number2
DOIs
Publication statusPublished - May 1 2013

Fingerprint

irinotecan
Rectal Neoplasms
Neoplasm Metastasis
Lung
Hepatectomy
Adjuvant Chemotherapy
Liver Neoplasms
Thigh
Amputation
Lymph Nodes
Drug Therapy
Neoplasms
panitumumab
Cetuximab
Bevacizumab

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

A case of panitumumab-responsive metastatic rectal cancer initially refractory to cetuximab. / Kasagi, Yuta; Oki, Eiji; Ando, Koji; Kimura, Yasue; Ikegami, Toru; Saeki, Hiroshi; Morita, Masaru; Kusumoto, Tetsuya; Maehara, Yoshihiko.

In: Case Reports in Oncology, Vol. 6, No. 2, 01.05.2013, p. 382-386.

Research output: Contribution to journalArticle

Kasagi, Yuta ; Oki, Eiji ; Ando, Koji ; Kimura, Yasue ; Ikegami, Toru ; Saeki, Hiroshi ; Morita, Masaru ; Kusumoto, Tetsuya ; Maehara, Yoshihiko. / A case of panitumumab-responsive metastatic rectal cancer initially refractory to cetuximab. In: Case Reports in Oncology. 2013 ; Vol. 6, No. 2. pp. 382-386.
@article{0a24f8da616c40749cae8f7efb1d9bf3,
title = "A case of panitumumab-responsive metastatic rectal cancer initially refractory to cetuximab",
abstract = "A 64-year-old man was initially diagnosed with rectal cancer and liver metastasis. He underwent rectal amputation and partial hepatectomy. mFOLFOX6 was begun as first-line chemotherapy, but multiple pulmonary and right femoral lymph node metastases were found 1 year postoperatively. FOLFIRI plus bevacizumab was then started, but the tumors recurred after 2 years and 11 months. The regimen was changed to cetuximab with CPT-11. The lesions partially responded after 3 months, and the patient was free from progression for 1.5 years. Four years and 7 months after the adjuvant chemotherapy was started, the metastatic lesions gradually increased again, and the regimen was changed to panitumumab. After 2 months, the lesions had markedly decreased again and showed a partial response for 6 months. Although the pulmonary lesions became progressive again, the patient has been alive for 5 years and 8 months since the first operation.",
author = "Yuta Kasagi and Eiji Oki and Koji Ando and Yasue Kimura and Toru Ikegami and Hiroshi Saeki and Masaru Morita and Tetsuya Kusumoto and Yoshihiko Maehara",
year = "2013",
month = "5",
day = "1",
doi = "10.1159/000353781",
language = "English",
volume = "6",
pages = "382--386",
journal = "Case Reports in Oncology",
issn = "1662-6575",
number = "2",

}

TY - JOUR

T1 - A case of panitumumab-responsive metastatic rectal cancer initially refractory to cetuximab

AU - Kasagi, Yuta

AU - Oki, Eiji

AU - Ando, Koji

AU - Kimura, Yasue

AU - Ikegami, Toru

AU - Saeki, Hiroshi

AU - Morita, Masaru

AU - Kusumoto, Tetsuya

AU - Maehara, Yoshihiko

PY - 2013/5/1

Y1 - 2013/5/1

N2 - A 64-year-old man was initially diagnosed with rectal cancer and liver metastasis. He underwent rectal amputation and partial hepatectomy. mFOLFOX6 was begun as first-line chemotherapy, but multiple pulmonary and right femoral lymph node metastases were found 1 year postoperatively. FOLFIRI plus bevacizumab was then started, but the tumors recurred after 2 years and 11 months. The regimen was changed to cetuximab with CPT-11. The lesions partially responded after 3 months, and the patient was free from progression for 1.5 years. Four years and 7 months after the adjuvant chemotherapy was started, the metastatic lesions gradually increased again, and the regimen was changed to panitumumab. After 2 months, the lesions had markedly decreased again and showed a partial response for 6 months. Although the pulmonary lesions became progressive again, the patient has been alive for 5 years and 8 months since the first operation.

AB - A 64-year-old man was initially diagnosed with rectal cancer and liver metastasis. He underwent rectal amputation and partial hepatectomy. mFOLFOX6 was begun as first-line chemotherapy, but multiple pulmonary and right femoral lymph node metastases were found 1 year postoperatively. FOLFIRI plus bevacizumab was then started, but the tumors recurred after 2 years and 11 months. The regimen was changed to cetuximab with CPT-11. The lesions partially responded after 3 months, and the patient was free from progression for 1.5 years. Four years and 7 months after the adjuvant chemotherapy was started, the metastatic lesions gradually increased again, and the regimen was changed to panitumumab. After 2 months, the lesions had markedly decreased again and showed a partial response for 6 months. Although the pulmonary lesions became progressive again, the patient has been alive for 5 years and 8 months since the first operation.

UR - http://www.scopus.com/inward/record.url?scp=84885577256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885577256&partnerID=8YFLogxK

U2 - 10.1159/000353781

DO - 10.1159/000353781

M3 - Article

C2 - 23904849

AN - SCOPUS:84885577256

VL - 6

SP - 382

EP - 386

JO - Case Reports in Oncology

JF - Case Reports in Oncology

SN - 1662-6575

IS - 2

ER -